739 Emerging proteomic and safety analysis of blood from solid tumor patients receiving TILT-123 (Ad5/3-E2F-d24-hTNFa-IRES-hIL2) monotherapy in TUNIMO phase 1 clinical trial

Documenti analoghi

• 739 Emerging proteomic and safety analysis of blood from solid tumor patients receiving TILT-123 (Ad5/3-E2F-d24-hTNFa-IRES-hIL2) monotherapy in TUNIMO phase 1 clinical trial
  di: Tuomo Alanko, et al.
  Pubblicazione: (2023-11-01)
• 749 Early phase oncology experience on the use of an oncolytic adenovirus encoding for TNFa and IL-2 for the treatment of solid tumors – Interim results
  di: Marco Donia, et al.
  Pubblicazione: (2023-11-01)
• 745 Immune cell profiling of advanced-stage solid tumors patients treated with an oncolytic adenovirus encoding for TNF-a and IL-2 (TILT-123)
  di: Tuomo Alanko, et al.
  Pubblicazione: (2023-11-01)
• 1518 T-cell inducing oncolytic virus (igrelimogene litadenorepvec; TILT-123) shows safety, anti-tumor activity and induction of immune responses in advanced solid tumor patients (full report on TUNIMO)
  di: Tuomo Alanko, et al.
  Pubblicazione: (2023-11-01)
• An oncolytic adenovirus coding for a variant interleukin 2 cytokine improves response to chemotherapy through enhancement of effector lymphocyte cytotoxicity, fibroblast compartment modulation and mitotic slippage
  di: Santeri Pakola, et al.
  Pubblicazione: (2023-07-01)